Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois Sells 13,551 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 13,551 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $412,356.93. Following the transaction, the chief executive officer now directly owns 418,519 shares in the company, valued at approximately $12,735,533.17. This trade represents a 3.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Cedric Francois also recently made the following trade(s):

• On Friday, January 17th, Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total transaction of $179,969.72.
• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total transaction of $179,288.90.

Apellis Pharmaceuticals Trading Up 1.2 %

Shares of APLS opened at $30.76 on Friday. The firm’s 50-day moving average is $31.95 and its two-hundred day moving average is $33.25. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The firm has a market capitalization of $3.83 billion, a P/E ratio of -15.15 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s revenue for the quarter was up 78.3% on a year-over-year basis. During the same period in the previous year, the business earned ($1.17) earnings per share. On average, research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Envestnet Asset Management Inc. grew its stake in Apellis Pharmaceuticals by 42.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after acquiring an additional 39,931 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after purchasing an additional 735,160 shares in the last quarter. Algert Global LLC grew its position in shares of Apellis Pharmaceuticals by 137.8% in the second quarter. Algert Global LLC now owns 123,628 shares of the company’s stock valued at $4,742,000 after purchasing an additional 71,650 shares during the last quarter. AlphaCentric Advisors LLC purchased a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth approximately $1,370,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth approximately $824,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. William Blair assumed coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They issued an “outperform” rating on the stock. Royal Bank of Canada restated a “sector perform” rating and issued a $26.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 14th. Wells Fargo & Company dropped their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Finally, Piper Sandler decreased their price target on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a report on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).